Midweek Movers, 4 New Targets

Wednesday’s Options Runners:

We got things right back on track with respect to our daily options ideas yesterday. Our premarket report contained a slate of four potential plays, and we saw some really nice intraday movement in all four of them. We have been on an incredible streak in this regard for all of 2024 so far, and as always, we’ll be trying our hardest to sustain that trend to the best of our ability. We sincerely thank all of our long-time and new readers alike for the incredible daily engagement and read rates!

Yesterday’s fresh targets were the VRT Weekly $56-54 Puts, the GRMN 03/25 $130 Calls, the PANW Weekly $280-275 Puts, and the PSA 03/15 $290-300 Calls, and here were the largest intraday runs posted by each of them on the day:

VRT Weekly $56-54 Puts
$56
: .31-1.20 (+287%)
$55: .15-.82 (+447%)
$54: .14-.55 (+293%)
_____

GRMN 03/25 $130 Calls
$130
: 2.94-8.60 (+192%)
_____

PANW Weekly $280-275 Puts
$280
: 12.20-20.30 (+66%)
$277.50: 10.59-17.15 (+62%)
$275: 8.80-16.18 (+84%)
_____

PSA 03/15 $290-300 Calls
$290
: 4.30-5.64 (+31%)
$300: 3.50-5.01 (+43%)


Fresh Options Ideas:
MRNA Weekly $91-93 Calls
TCOM 03/15 $44-45 Calls
PANW Weekly $260-270 Calls
NVDA Weekly $755-765 Calls


Extended Watchlist:
MNPR, AGRX, VERO, BZFD, EAST, GMBL, TSPH, ASPU

Key Recaps, 4 Fresh Options Ideas

Recap of Friday’s Options Plays:

For those who took Monday’s break to relax and may have missed out on our relaying of Friday’s activity, we’re going to drop the recap of those plays one more time this morning. We didn’t do so yesterday of course, because we gave sole focus for the day to a special report on a new company that has engaged us for investor relations. We urge those who might have missed that report to click here and read it now.

As for our last active options ideas, here are those figures from Friday’s report one more time, and today we’ll do our best to generate some more good ideas today:

COIN Weekly $185-190
$185
: 1.85-8.58 (+364%)
$190: .72-4.95 (+587%)
_____

MARA Weekly $27.50-28.50 Calls
$28: .09-.78 (+767%)
_____

TTD Weekly $87-89 Calls
$87: 1.01-3.66 (+264%)
$88: .76-2.83 (+272%)
$89: .54-2.03 (+276%)


Fresh Options Ideas:
VRT Weekly $56-54 Puts
GRMN 03/25 $130 Calls
PANW Weekly $280-275 Puts
PSA 03/15 $290-300 Calls


AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) – Recap:

We recently tagged AGRI on Feb. 9th, and caught the stock at a subsequent low of .20. Yesterday it registered a new high of .706, which equates to a respectable rise of 253% over the past couple of weeks.

It’s always pleasing to find NASDAQ plays that are making OTC level runs in such short periods of time, and another reason why it’s a good idea to pay as much attention to our extended watchlist plays as you do to our featured content!


Extended Watchlist:
IVP, SOGP, EFOI, GBNH, SEED, VCIG, MOTS, AABB, SHMP, CBIA, TONR

OTC Medical Cannabis Special Report

Cannabis Bioscience International Holdings, Inc. (OTCMKTS:CBIH) Special Report:

For today’s report, we’re excited to be profiling Cannabis Bioscience International Holdings (“CBIH“), an intriguing cannabis company that has its sights set on securing a piece of the massive global CBD (Cannabidiol) market. CBD is expected to enjoy a compound annual growth rate of nearly 50%, reaching a market valuation of over $55 billion by 2028 (according to cbih.net).

As we’ve recently mentioned, we’ve had loads of experience with OTC Cannabis stocks and we can recognize a good ground-floor opportunity when we see one. Right now, CBIH appears to have all the pieces in place to write a very compelling story in 2024 and beyond. CBIH has been hard at work developing multiple CBD-based treatments for osteoarthritis, anxiety, PTSD, and an array of other common physical and psychological afflictions, with the intention of running a full gamut of clinical trials to prove their effectiveness.

In a recent letter to shareholders (via Newsfile Corp), company CEO Dante Picazo communicated his excitement over one CBIH product in particular- Orthocann. It is his belief that it could become the world’s first intra-articular injection for the treatment of osteoarthritis, to actually help rebuild tissues which have been damaged by the disease. While certainly an intriguing prospect, it is also the company’s intent to market Orthocann as an ointment and a capsule as well.

According to Medical News Today, roughly half a billion people (~7% of the global population) suffer from this most common form of arthritis that primarily affects people over 40-50 years of age. That’s well over 30 million individuals in the US alone, which is obviously a huge market for CBIH to target with Orthocann. Considering that we are a country with a rapidly increasing elderly population, one would also expect those figures to climb higher by the year.

In addition to a full line of CBD formulations, CBIH is also in the business of medicinal cannabis education, offering tools to the public via Pharmacology University, an online learning platform to educate individuals on the chemistry, cultivation, and many benefits of, and opportunities presented by, cannabis and its byproducts. In this regard, we feel that CBIH is acting as an excellent ambassador for the medical cannabis industry at large.

Stay tuned for future updates on Cannabis Bioscience International Holdings, and its big plans for 2024. 


NEW CBIH NEWS: 

This morning, CBIH has officially announced its engagement of our parent company to help transform its approach to investor relations, and aid in bringing the company’s vision for the future to life. A charge that we take very seriously, and are honored to undertake.

HOUSTON, TX–(NewsFile Corp. – February 20, 2024) – Cannabis Bioscience International Holdings, a Houston-based company trading on the OTC Markets under the ticker symbol CBIH, has engaged the services of Bull in Advantage as its Investor Relations firm. (>>VIEW PR)


For more information on CBIH, please visit cbih.net
and/or contact Peter Nicosia at (585) 703-6565 with any inquiries.